Report from the 63rd American Society of Hematology Annual Meeting — Benign Hematology

Highlights of the latest research.

Presenters at the 2021 meeting of the American Society of Hematology (ASH; December 11–14, 2021) reported the latest research in hematology. Here, NEJM Journal Watch Oncology and Hematology Associate Editor Dr. Brady L. Stein describes the key findings in benign hematology.

Prophylactic Fitusiran Reduces Bleeding in Certain Patients with Hemophilia

Prophylactic use of fitusiran, an investigational small interfering RNA (siRNA) therapeutic, is associated with a lower bleeding rate than on-demand bypassing agents (BPA) in people with hemophilia A or B with inhibitors, according to the industry-conducted, phase 3 ATLAS-INH study (abstract 4).

Nearly 60 males with hemophilia A or B with inhibitors who were taking on-demand BPA were randomized to r…

Author

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Report from the 63rd American Society of Hematology Annual Meeting — Benign Hematology

Topics

Prophylactic Fitusiran Reduces Bleeding in Certain Patients with Hemophilia

Author